BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24429300)

  • 1. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis.
    Ni J; Qiu LJ; Hu LF; Cen H; Zhang M; Wen PF; Wang XS; Pan HF; Ye DQ
    Lupus; 2014 Mar; 23(3):284-92. PubMed ID: 24429300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.
    Dreyer L; Faurschou M; Mogensen M; Jacobsen S
    Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies.
    Onishi A; Sugiyama D; Kumagai S; Morinobu A
    Arthritis Rheum; 2013 Jul; 65(7):1913-21. PubMed ID: 23576072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.
    Huang HB; Jiang SC; Han J; Cheng QS; Dong CB; Pan CM
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1067-73. PubMed ID: 24525705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies.
    Apor E; O'Brien J; Stephen M; Castillo JJ
    Leuk Res; 2014 Sep; 38(9):1067-71. PubMed ID: 25052307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic lupus erythematous and malignancy risk: a meta-analysis.
    Cao L; Tong H; Xu G; Liu P; Meng H; Wang J; Zhao X; Tang Y; Jin J
    PLoS One; 2015; 10(4):e0122964. PubMed ID: 25885411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international cohort study of cancer in systemic lupus erythematosus.
    Bernatsky S; Boivin JF; Joseph L; Rajan R; Zoma A; Manzi S; Ginzler E; Urowitz M; Gladman D; Fortin PR; Petri M; Edworthy S; Barr S; Gordon C; Bae SC; Sibley J; Isenberg D; Rahman A; Aranow C; Dooley MA; Steinsson K; Nived O; Sturfelt G; Alarcón G; Senécal JL; Zummer M; Hanly J; Ensworth S; Pope J; El-Gabalawy H; McCarthy T; St Pierre Y; Ramsey-Goldman R; Clarke A
    Arthritis Rheum; 2005 May; 52(5):1481-90. PubMed ID: 15880596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid cancer in systemic lupus erythematosus: a meta analysis.
    Zhang M; Li XM; Wang GS; Qian L; Tao JH; Ma Y; Li XP
    Int J Clin Exp Pathol; 2014; 7(9):6270-3. PubMed ID: 25337279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of malignancy in patients with systemic lupus erythematosus.
    Ramsey-Goldman R; Mattai SA; Schilling E; Chiu YL; Alo CJ; Howe HL; Manzi S
    J Investig Med; 1998 Jun; 46(5):217-22. PubMed ID: 9676054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
    Zintzaras E; Voulgarelis M; Moutsopoulos HM
    Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials.
    Rusthoven KE; Flaig TW; Raben D; Kavanagh BD
    Clin Lung Cancer; 2008 Mar; 9(2):106-11. PubMed ID: 18501097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The age-risk relationship of haematologic malignancies in female patients with systemic lupus erythematosus: a nationwide retrospective cohort study.
    Lin YC; Yen JH; Chang SJ; Lin YC
    Lupus; 2012 Oct; 21(11):1250-6. PubMed ID: 22740427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic lupus erythematosus and the risk of malignancy.
    Cibere J; Sibley J; Haga M
    Lupus; 2001; 10(6):394-400. PubMed ID: 11434573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of independent second malignancies after non-muscle-invasive bladder cancer.
    Zecha H; Schmid HP; Tschopp A; Sulser T; Engeler DS
    Scand J Urol Nephrol; 2011 Sep; 45(4):245-50. PubMed ID: 21443417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus.
    Mok CC; Ho LY; To CH
    Scand J Rheumatol; 2009; 38(5):362-8. PubMed ID: 19296403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
    Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
    J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study.
    Bengtsson C; Ohman ML; Nived O; Rantapää Dahlqvist S
    Lupus; 2012 Apr; 21(4):452-9. PubMed ID: 22065097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin's lymphoma in systemic lupus erythematosus.
    Bernatsky S; Ramsey-Goldman R; Isenberg D; Rahman A; Dooley MA; Sibley J; Boivin JF; Joseph L; Armitage J; Zoma A; Clarke A
    Rheumatology (Oxford); 2007 May; 46(5):830-2. PubMed ID: 17255135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.
    Parikh-Patel A; White RH; Allen M; Cress R
    Cancer Causes Control; 2008 Oct; 19(8):887-94. PubMed ID: 18386139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.